Skip to main content
Signal8
Launch Terminal

Celcuity Inc. (CELC)

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Sector: Services-Medical Laboratories

Industry: Biotechnology

Celcuity Inc. logo

Celcuity Inc.

NASDAQ:CELCHealthcare
-0.25%$69.13
AH$69.29+0.23%vs close
Mkt Cap$3.38B
Float39.83M
O/S48.93M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Celcuity Inc. logoNASDAQ:CELC$69.13-0.25%
Phase Distribution
5 lead-sponsored trials·3 active·1 completed
Phase 11
Phase 1/21
Phase 32
Not applicable1
(6 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting1
Completed1
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

    Gedatolisib, Palbociclib

    Breast Cancer

    Enrollment
    701
    Start
    Dec 2022
    Primary Completion
    Jun 2026est.
    Completion
    Dec 2026est.
    NCT05501886
  • Phase 3
    Recruiting

    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant

    Breast Cancer

    Enrollment
    1,180
    Start
    Jul 2025
    Primary Completion
    Mar 2029est.
    Completion
    Jul 2033est.
    NCT06757634
  • Phase 1/2
    Recruiting

    Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

    Gedatolisib, Darolutamide

    mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male +4

    Enrollment
    54
    Start
    Jan 2024
    Primary Completion
    Jan 2028est.
    Completion
    Jan 2030est.
    NCT06190899
  • Phase 1
    Completed

    A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

    Gedatolisib, Palbociclib

    Breast Cancer

    Enrollment
    141
    Start
    Jun 2016
    Primary Completion
    Jan 2022
    Completion
    Jan 2022
    NCT02684032
  • Expanded access
    Available

    Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

    Gedatolisib

    Breast Neoplasm Malignant Female

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT05134922
Search ClinicalTrials.gov for “Celcuity”